Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL14976365 | 0.98 | KIF11 (0.95) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Water SCHEMBL11129297 | 0.98 | KIF11 (0.95) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6226052 | 0.91 | KIF11 (0.83) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Iodide SCHEMBL5092391 | 0.89 | KIF11 (0.80) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Iodide SCHEMBL5092420 | 0.89 | KIF11 (0.80) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL5087839 | 0.89 | KIF11 (0.80) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5085141 | 0.89 | KIF11 (0.80) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5086796 | 0.89 | KIF11 (0.80) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL5085165 | 0.89 | KIF11 (0.80) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3414508 | 0.85 | KIF11 (0.74) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11993556-B1 | Peptoid-based inhibitors of the protein arginine methyltransferase (PRMT) family | UNIVERSITY OF NORTH FLORIDA BOARD OF TRUSTEES (US) | 2024-05-28 | — | — | US | disclosed |
| US-8796908-B2 | Piezoelectric body, ultrasound transducer, medical ultrasound diagnostic system, and nondestructive ultrasound test system | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20120121509-A1 | VITAL FLUOROCHROME CONJUGATES AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120116228-A1 | PIEZOELECTRIC BODY, ULTRASOUND TRANSDUCER, MEDICAL ULTRASOUND DIAGNOSTIC SYSTEM, AND NONDESTRUCTIVE ULTRASOUND TEST SYSTEM | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-6391535-B1 | SUBLAYER CONTAINING AN INFRARED ABSORBING METHINE CYANINE DYE EXHIBITING AN ABSORPTION MAXIMUM AT A WAVELENGTH OF 700 TO 900 NM; EXHIBITING ANTIHALATION EFFECTS, SUPERIOR SHARPNESS AND WITH NO UNEVEN DENSITY DUE TO INTERFERENCE FRINGES | KONICA CORPORATION (JP) | 2002-05-21 | — | — | US | disclosed |
| US-6309564-B1 | Optical filter comprising transparent support and filter layer containing dye and binder polymer | FUJI PHOTO FILM CO., LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121509-A1 | VITAL FLUOROCHROME CONJUGATES AND METHODS OF USE | CASP3, CASP7, CD47 | KIF11 1884/4885KCNH2 1377/4885CYP3A4 2506/4885 |
| US-11993556-B1 | Peptoid-based inhibitors of the protein arginine methyltransferase (PRMT) family | PRMT1, PRMT3, PRMT5 | KIF11 3606/4885KCNH2 4831/4885CYP3A4 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.